Exploring the efficacy of XAV939 and LF3 in targeting β-catenin signalling in gallbladder cancer cell lines

PURPOSE: Gallbladder cancer (GBC) is a common biliary malignancy in India, with poor prognosis and disappointing outcomes despite radical surgery, including high recurrence rates and low 5-year survival. This underscores the urgent need for more effective treatments. Recent research highlights the WNT/β-catenin signalling pathway upregulation in GBC, suggesting it as a promising therapeutic target. METHODS: values of both inhibitors, and Western blotting was employed to assess β-catenin expression and its downstream transcriptional targets. We also examined changes in cell migration, invasion, and colony formation, and assessed nuclear β-catenin inhibition via immunofluorescence. RESULTS: values of 100µM for OCUG1 and 50µM for NOZ cells. LF3 treatment reduced β-catenin and its downstream targets: c-Myc, and cyclin D1 expression at sub-optimal doses, showing superior efficacy compared to XAV939. CONCLUSIONS: Compared to XAV939, LF3 more effectively inhibits nuclear β-catenin, might resulting in lower off-target toxicity and making it a favorable clinical candidate for targeting GBCs.